Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cerevel Therapeutics Holdings, Inc. (ARYB) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cerevel Therapeutics Holdings, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1805387.
Total stock buying since 2020: $793,396,535.
Total stock sales since 2020: $53,065,221.
Total stock option exercises since 2020: $6,664,226.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 229,667 | $9,548,809 | 245,460 | $787,500 |
| 2023 | 16,545,893 | $377,510,547 | 803,666 | $24,989,386 | 858,831 | $2,449,587 |
| 2022 | 1,425,000 | $49,875,000 | 431,371 | $14,549,872 | 459,911 | $2,907,565 |
| 2021 | 464,716 | $12,166,300 | 110,000 | $3,977,154 | 191,260 | $519,574 |
| 2020 | 35,354,174 | $353,844,688 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-07 | 0 | $0 | 25,000 | $1,029,524 | 25,000 | $87,500 |
| 2024-05 | 0 | $0 | 50,000 | $2,105,150 | 50,000 | $175,000 |
| 2024-03 | 0 | $0 | 50,000 | $2,050,550 | 50,000 | $175,000 |
| 2024-02 | 0 | $0 | 54,667 | $2,251,785 | 70,460 | $175,000 |
| 2024-01 | 0 | $0 | 50,000 | $2,111,800 | 50,000 | $175,000 |
| 2023-12 | 0 | $0 | 94,465 | $3,863,735 | 346,792 | $399,232 |
| 2023-11 | 0 | $0 | 157,306 | $3,967,034 | 157,306 | $825,355 |
| 2023-10 | 16,440,156 | $374,999,958 | 0 | $0 | 0 | $0 |
| 2023-09 | 0 | $0 | 50,000 | $1,203,400 | 50,000 | $175,000 |
| 2023-08 | 105,737 | $2,510,589 | 0 | $0 | 0 | $0 |
| 2023-07 | 0 | $0 | 50,000 | $1,501,350 | 50,000 | $175,000 |
| 2023-06 | 0 | $0 | 251,895 | $8,578,490 | 54,733 | $175,000 |
| 2023-05 | 0 | $0 | 50,000 | $1,600,850 | 50,000 | $175,000 |
| 2023-04 | 0 | $0 | 50,000 | $1,253,150 | 50,000 | $175,000 |
| 2023-03 | 0 | $0 | 50,000 | $1,355,928 | 50,000 | $175,000 |
| 2023-02 | 0 | $0 | 50,000 | $1,665,449 | 50,000 | $175,000 |
| 2022-08 | 1,425,000 | $49,875,000 | 210,266 | $7,542,345 | 210,266 | $2,133,698 |
| 2022-07 | 0 | $0 | 51,105 | $1,535,912 | 51,105 | $178,867 |
| 2022-06 | 0 | $0 | 0 | $0 | 14,270 | $0 |
| 2022-04 | 0 | $0 | 45,000 | $1,559,115 | 45,000 | $157,500 |
| 2022-03 | 0 | $0 | 100,000 | $3,162,500 | 100,000 | $350,000 |
| 2022-02 | 0 | $0 | 25,000 | $750,000 | 25,000 | $87,500 |
| 2022-01 | 0 | $0 | 0 | $0 | 14,270 | $0 |
| 2021-12 | 0 | $0 | 55,000 | $1,750,479 | 55,000 | $192,499 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-07-01 | Coles N Anthony | Sale | 25,000 | 41.18 | 1,029,524 |
| 2024-07-01 | Coles N Anthony | Option Ex | 25,000 | 3.50 | 87,500 |
| 2024-05-10 | Coles N Anthony | Sale | 50,000 | 42.10 | 2,105,150 |
| 2024-05-10 | Coles N Anthony | Option Ex | 50,000 | 3.50 | 175,000 |
| 2024-03-04 | Coles N Anthony | Sale | 50,000 | 41.01 | 2,050,550 |
| 2024-03-04 | Coles N Anthony | Option Ex | 50,000 | 3.50 | 175,000 |
| 2024-02-29 | Coles N Anthony | Sale | 50,000 | 41.16 | 2,057,900 |
| 2024-02-29 | Coles N Anthony | Option Ex | 50,000 | 3.50 | 175,000 |
| 2024-02-07 | Renger John (Chief Scientific Officer) | Sale | 2,161 | 41.54 | 89,776 |
| 2024-02-07 | Coles N Anthony | Sale | 2,506 | 41.54 | 104,109 |
| 2024-02-06 | Renger John (Chief Scientific Officer) | Option Ex | 5,020 | .00 | 0 |
| 2024-02-06 | Coles N Anthony | Option Ex | 15,440 | .00 | 0 |
| 2024-01-02 | Coles N Anthony | Sale | 50,000 | 42.24 | 2,111,800 |
| 2024-01-02 | Coles N Anthony | Option Ex | 50,000 | 3.50 | 175,000 |
| 2023-12-26 | Tregoning Kathleen (See Remarks) | Option Ex | 3,150 | 10.05 | 31,657 |
| 2023-12-22 | Dipietro Kenneth (Chief Human Resources Officer) | Sale | 8,000 | 41.45 | 331,608 |
| 2023-12-22 | Dipietro Kenneth (Chief Human Resources Officer) | Option Ex | 8,000 | 3.50 | 28,000 |
| 2023-12-20 | Tregoning Kathleen (See Remarks) | Sale | 6,288 | 41.42 | 260,467 |
| 2023-12-20 | Bodenrader Mark (See Remarks) | Sale | 7,889 | 41.42 | 326,786 |
| 2023-12-20 | Sanchez Ramiro (Chief Medical Officer) | Sale | 10,152 | 41.42 | 420,526 |
| 2023-12-20 | Altschuller Susan (Chief Financial Officer) | Sale | 13,808 | 41.42 | 571,968 |
| 2023-12-20 | Akamine Scott (Chief Legal Officer) | Sale | 7,072 | 41.42 | 292,943 |
| 2023-12-20 | Dipietro Kenneth (Chief Human Resources Officer) | Sale | 6,256 | 41.42 | 259,142 |
| 2023-12-19 | Tregoning Kathleen (See Remarks) | Option Ex | 13,804 | .00 | 0 |
| 2023-12-19 | Bodenrader Mark (See Remarks) | Option Ex | 19,284 | .00 | 0 |
| 2023-12-19 | Sanchez Ramiro (Chief Medical Officer) | Option Ex | 24,825 | .00 | 0 |
| 2023-12-19 | Altschuller Susan (Chief Financial Officer) | Option Ex | 30,721 | .00 | 0 |
| 2023-12-19 | Akamine Scott (Chief Legal Officer) | Option Ex | 13,796 | .00 | 0 |
| 2023-12-19 | Burgess Paul D. (See Remarks) | Option Ex | 23,847 | .00 | 0 |
| 2023-12-19 | Dipietro Kenneth (Chief Human Resources Officer) | Option Ex | 13,913 | .00 | 0 |
| 2023-12-19 | Renaud Ronald C Jr (President & CEO) | Option Ex | 160,452 | .00 | 0 |
| 2023-12-15 | Sanchez Ramiro (Chief Medical Officer) | Sale | 7,500 | 41.39 | 310,395 |
| 2023-12-15 | Sanchez Ramiro (Chief Medical Officer) | Option Ex | 7,500 | 9.88 | 74,100 |
| 2023-12-07 | Sanchez Ramiro (Chief Medical Officer) | Sale | 10,000 | 41.37 | 413,700 |
| 2023-12-07 | Sanchez Ramiro (Chief Medical Officer) | Option Ex | 10,000 | 3.50 | 35,000 |
| 2023-12-07 | Akamine Scott (Chief Legal Officer) | Sale | 10,000 | 41.37 | 413,700 |
| 2023-12-07 | Akamine Scott (Chief Legal Officer) | Option Ex | 10,000 | 13.17 | 131,700 |
| 2023-12-05 | Akamine Scott (Chief Legal Officer) | Sale | 7,500 | 35.00 | 262,500 |
| 2023-12-05 | Akamine Scott (Chief Legal Officer) | Option Ex | 7,500 | 13.17 | 98,775 |
| 2023-11-08 | Coles N Anthony | Sale | 100 | 25.16 | 2,516 |
| 2023-11-08 | Coles N Anthony | Option Ex | 100 | 3.50 | 350 |
| 2023-11-07 | Coles N Anthony | Sale | 27,076 | 25.02 | 677,549 |
| 2023-11-07 | Coles N Anthony | Option Ex | 27,076 | 3.50 | 94,766 |
| 2023-11-03 | Coles N Anthony | Sale | 61,401 | 25.43 | 1,561,488 |
| 2023-11-03 | Coles N Anthony | Option Ex | 61,401 | 3.50 | 214,903 |
| 2023-11-02 | Coles N Anthony | Sale | 38,599 | 25.19 | 972,231 |
| 2023-11-02 | Coles N Anthony | Option Ex | 38,599 | 3.50 | 135,096 |
| 2023-11-01 | Patrick Deval L | Sale | 30,130 | 25.00 | 753,250 |
| 2023-11-01 | Patrick Deval L | Option Ex | 30,130 | 12.62 | 380,240 |
| 2023-10-16 | Bain Capital Partners Xii, Llc (10% Owner) | Buy | 5,480,052 | 22.81 | 124,999,986 |
| 2023-10-16 | Koppel Adam (Director) | Buy | 5,480,052 | 22.81 | 124,999,986 |
| 2023-10-16 | Gordon Christopher R (Director) | Buy | 5,480,052 | 22.81 | 124,999,986 |
| 2023-09-07 | Coles N Anthony | Sale | 50,000 | 24.07 | 1,203,400 |
| 2023-09-07 | Coles N Anthony | Option Ex | 50,000 | 3.50 | 175,000 |
| 2023-08-04 | Burgess Paul D. (See Remarks) | Buy | 21,880 | 22.93 | 501,795 |
| 2023-08-03 | Renaud Ronald C Jr (President & CEO) | Buy | 83,857 | 23.95 | 2,008,794 |
| 2023-07-11 | Coles N Anthony | Sale | 50,000 | 30.03 | 1,501,350 |
| 2023-07-11 | Coles N Anthony | Option Ex | 50,000 | 3.50 | 175,000 |
| 2023-06-15 | Dekkers Marijn E | Sale | 200,000 | 34.43 | 6,886,000 |
| 2023-06-02 | Bodenrader Mark (See Remarks) | Sale | 1,895 | 32.95 | 62,440 |
| 2023-06-01 | Bodenrader Mark (See Remarks) | Option Ex | 4,733 | .00 | 0 |
| 2023-06-01 | Coles N Anthony (CEO and Chairperson) | Sale | 50,000 | 32.60 | 1,630,050 |
| 2023-06-01 | Coles N Anthony (CEO and Chairperson) | Option Ex | 50,000 | 3.50 | 175,000 |
| 2023-05-04 | Coles N Anthony (CEO and Chairperson) | Sale | 50,000 | 32.02 | 1,600,850 |
| 2023-05-04 | Coles N Anthony (CEO and Chairperson) | Option Ex | 50,000 | 3.50 | 175,000 |
| 2023-04-11 | Coles N Anthony (CEO and Chairperson) | Sale | 50,000 | 25.06 | 1,253,150 |
| 2023-04-11 | Coles N Anthony (CEO and Chairperson) | Option Ex | 50,000 | 3.50 | 175,000 |
| 2023-03-03 | Coles N Anthony (CEO and Chairperson) | Sale | 3,000 | 27.19 | 81,570 |
| 2023-03-03 | Coles N Anthony (CEO and Chairperson) | Option Ex | 3,000 | 3.50 | 10,500 |
| 2023-03-02 | Coles N Anthony (CEO and Chairperson) | Sale | 47,000 | 27.11 | 1,274,358 |
| 2023-03-02 | Coles N Anthony (CEO and Chairperson) | Option Ex | 47,000 | 3.50 | 164,500 |
| 2023-02-07 | Coles N Anthony (CEO and Chairperson) | Sale | 50,000 | 33.31 | 1,665,449 |
| 2023-02-07 | Coles N Anthony (CEO and Chairperson) | Option Ex | 50,000 | 3.50 | 175,000 |
| 2022-08-22 | Ceesay Abraham (President) | Sale | 28,815 | 32.50 | 936,486 |
| 2022-08-22 | Ceesay Abraham (President) | Option Ex | 28,815 | 13.17 | 379,491 |
| 2022-08-16 | Edelman Joseph (Director) | Buy | 1,425,000 | 35.00 | 49,875,000 |
| 2022-08-15 | Ceesay Abraham (President) | Sale | 9,606 | 34.12 | 327,756 |
| 2022-08-15 | Ceesay Abraham (President) | Option Ex | 9,606 | 13.17 | 126,511 |
| 2022-08-10 | Renger John (Chief Scientific Officer) | Sale | 55,000 | 40.65 | 2,235,475 |
| 2022-08-10 | Renger John (Chief Scientific Officer) | Option Ex | 55,000 | 6.89 | 378,950 |
| 2022-08-08 | Renger John (Chief Scientific Officer) | Sale | 10,000 | 37.75 | 377,500 |
| 2022-08-08 | Renger John (Chief Scientific Officer) | Option Ex | 10,000 | 3.50 | 35,000 |
| 2022-08-08 | Akamine Scott (Chief Legal Officer) | Sale | 10,000 | 40.00 | 400,000 |
| 2022-08-08 | Akamine Scott (Chief Legal Officer) | Option Ex | 10,000 | 13.17 | 131,700 |
| 2022-08-08 | Ceesay Abraham (President) | Sale | 19,211 | 38.62 | 742,024 |
| 2022-08-08 | Ceesay Abraham (President) | Option Ex | 19,211 | 13.17 | 253,008 |
| 2022-08-05 | Renger John (Chief Scientific Officer) | Sale | 20,000 | 32.50 | 650,000 |
| 2022-08-05 | Renger John (Chief Scientific Officer) | Option Ex | 20,000 | 3.50 | 70,000 |
| 2022-08-05 | Ceesay Abraham (President) | Sale | 38,424 | 32.50 | 1,248,780 |
| 2022-08-05 | Ceesay Abraham (President) | Option Ex | 38,424 | 13.17 | 506,044 |
| 2022-07-20 | Renger John (Chief Scientific Officer) | Sale | 25,000 | 30.00 | 750,000 |
| 2022-07-20 | Renger John (Chief Scientific Officer) | Option Ex | 25,000 | 3.50 | 87,500 |
| 2022-07-06 | Renger John (Chief Scientific Officer) | Sale | 1,105 | 32.50 | 35,912 |
| 2022-07-06 | Renger John (Chief Scientific Officer) | Option Ex | 1,105 | 3.50 | 3,867 |
| 2022-07-05 | Renger John (Chief Scientific Officer) | Sale | 25,000 | 30.00 | 750,000 |
| 2022-07-05 | Renger John (Chief Scientific Officer) | Option Ex | 25,000 | 3.50 | 87,500 |
| 2022-06-24 | Sulzberger Gabrielle (Director) | Option Ex | 14,270 | .00 | 0 |
| 2022-04-13 | Renger John (Chief Scientific Officer) | Sale | 45,000 | 34.65 | 1,559,115 |
| 2022-04-13 | Renger John (Chief Scientific Officer) | Option Ex | 45,000 | 3.50 | 157,500 |
| 2022-03-18 | Renger John (Chief Scientific Officer) | Sale | 20,000 | 32.50 | 650,000 |
| 2022-03-18 | Renger John (Chief Scientific Officer) | Option Ex | 20,000 | 3.50 | 70,000 |
| 2022-03-16 | Renger John (Chief Scientific Officer) | Sale | 25,000 | 30.00 | 750,000 |
| 2022-03-16 | Renger John (Chief Scientific Officer) | Option Ex | 25,000 | 3.50 | 87,500 |
| 2022-03-09 | Renger John (Chief Scientific Officer) | Sale | 30,000 | 33.75 | 1,012,500 |
| 2022-03-09 | Renger John (Chief Scientific Officer) | Option Ex | 30,000 | 3.50 | 105,000 |
| 2022-03-02 | Renger John (Chief Scientific Officer) | Sale | 25,000 | 30.00 | 750,000 |
| 2022-03-02 | Renger John (Chief Scientific Officer) | Option Ex | 25,000 | 3.50 | 87,500 |
| 2022-02-09 | Renger John (Chief Scientific Officer) | Sale | 25,000 | 30.00 | 750,000 |
| 2022-02-09 | Renger John (Chief Scientific Officer) | Option Ex | 25,000 | 3.50 | 87,500 |
| 2022-01-04 | Riedel Norbert G (Director) | Option Ex | 14,270 | .00 | 0 |
| 2021-12-27 | Renger John (Chief Scientific Officer) | Sale | 4,127 | 35.00 | 144,445 |
| 2021-12-27 | Renger John (Chief Scientific Officer) | Option Ex | 4,127 | 3.50 | 14,444 |
| 2021-12-23 | Renger John (Chief Scientific Officer) | Sale | 5,873 | 35.01 | 205,584 |
| 2021-12-23 | Renger John (Chief Scientific Officer) | Option Ex | 5,873 | 3.50 | 20,555 |
| 2021-12-21 | Renger John (Chief Scientific Officer) | Sale | 7,300 | 32.50 | 237,250 |
| 2021-12-21 | Renger John (Chief Scientific Officer) | Option Ex | 7,300 | 3.50 | 25,550 |
| 2021-12-17 | Renger John (Chief Scientific Officer) | Sale | 7,122 | 32.50 | 231,465 |
| 2021-12-17 | Renger John (Chief Scientific Officer) | Option Ex | 7,122 | 3.50 | 24,927 |
| 2021-12-16 | Renger John (Chief Scientific Officer) | Sale | 5,578 | 32.50 | 181,285 |
| 2021-12-16 | Renger John (Chief Scientific Officer) | Option Ex | 5,578 | 3.50 | 19,523 |
| 2021-12-15 | Renger John (Chief Scientific Officer) | Sale | 25,000 | 30.02 | 750,450 |
| 2021-12-15 | Renger John (Chief Scientific Officer) | Option Ex | 25,000 | 3.50 | 87,500 |
| 2021-11-10 | Renger John (Chief Scientific Officer) | Sale | 55,000 | 40.48 | 2,226,675 |
| 2021-11-10 | Renger John (Chief Scientific Officer) | Option Ex | 55,000 | 3.50 | 192,500 |
| 2021-09-24 | Dekkers Marijn E (Director) | Option Ex | 14,270 | .00 | 0 |
| 2021-08-26 | Edelman Joseph (Director) | Buy | 68,047 | 30.23 | 2,057,060 |
| 2021-08-25 | Edelman Joseph (Director) | Buy | 61,387 | 28.57 | 1,753,826 |
| 2021-08-24 | Edelman Joseph (Director) | Buy | 69,761 | 27.73 | 1,934,472 |
| 2021-08-23 | Edelman Joseph (Director) | Buy | 44,437 | 25.78 | 1,145,585 |
| 2021-07-07 | Edelman Joseph (Director) | Buy | 200,000 | 25.00 | 5,000,000 |
| 2021-06-24 | Sulzberger Gabrielle (Director) | Option Ex | 14,270 | .00 | 0 |
| 2021-06-17 | Sulzberger Gabrielle (Director) | Buy | 21,084 | 13.06 | 275,357 |
| 2021-01-26 | Mishan Orly (Chief Business Officer) | Option Ex | 38,450 | 3.50 | 134,575 |
| 2021-01-04 | Riedel Norbert G (Director) | Option Ex | 14,270 | .00 | 0 |
| 2020-11-09 | Bain Capital Partners Xii, Llc (10% Owner) | Buy | 332,293 | 10.30 | 3,422,617 |
| 2020-11-09 | Koppel Adam (Director) | Buy | 332,293 | 10.30 | 3,422,617 |
| 2020-11-09 | Gordon Christopher R (Director) | Buy | 332,293 | 10.30 | 3,422,617 |
| 2020-10-27 | Bain Capital Partners Xii, Llc (10% Owner) | Buy | 10,000,000 | 10.00 | 100,000,000 |
| 2020-10-27 | Koppel Adam (Director) | Buy | 10,000,000 | 10.00 | 100,000,000 |
| 2020-10-27 | Gordon Christopher R (Director) | Buy | 10,000,000 | 10.00 | 100,000,000 |
| 2020-10-27 | Edelman Joseph (Director) | Buy | 3,000,000 | 10.00 | 30,000,000 |
| 2020-10-27 | Pfizer Inc (10% Owner) | Buy | 1,200,000 | 10.00 | 12,000,000 |
| 2020-10-21 | Edelman Joseph (Director) | Buy | 43,195 | 10.09 | 435,837 |
| 2020-10-20 | Edelman Joseph (Director) | Buy | 114,100 | 10.00 | 1,141,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ARYB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cerevel Therapeutics Holdings, Inc. (symbol ARYB, CIK number 1805387) see the Securities and Exchange Commission (SEC) website.